# Efficacy, Safety of Coadministered Pitavastatin and Valsartan in Patients With Hypertension and Dyslipidemia

Study · id `cardio:ct-nct01402843` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01402843](<https://clinicaltrials.gov/study/NCT01402843>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01402843

Browse, organ or system: Blood vessels; Metabolism  
Browse, condition area: Risk and prevention; High blood pressure; Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It plans to enroll 150 participants.

## Technical summary

Registry record NCT01402843. Randomized; quadruple masking; primary purpose treatment. Start 2011-06 (registry gives no type); primary completion 2012-06 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 150 participants (planned count; ClinicalTrials.gov record NCT01402843, source copy `cardio:ctgov-nct01402843-2014-05-14`, retrieved 2026-10-26)
- Start date: 2011-06 (registry gives no type) (ClinicalTrials.gov record NCT01402843, source copy `cardio:ctgov-nct01402843-2014-05-14`, retrieved 2026-10-26)
- Primary completion: 2012-06 (actual) (ClinicalTrials.gov record NCT01402843, source copy `cardio:ctgov-nct01402843-2014-05-14`, retrieved 2026-10-26)
- Completion: 2013-01 (actual) (ClinicalTrials.gov record NCT01402843, source copy `cardio:ctgov-nct01402843-2014-05-14`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT01402843, source copy `cardio:ctgov-nct01402843-2014-05-14`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01402843-2014-05-14`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy, Safety of Coadministered Pitavastatin and Valsartan in Patients With Hypertension and Dyslipidemia
- Acronym: COCTAIL
- Condition: Hypertension
- Condition: Dyslipidemia
- Intervention (Drug): pitavastatin, valsartan, placebo
- Lead sponsor: JW Pharmaceutical
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry lists this organization as the lead sponsor: JW Pharmaceutical (`cardio:org-jw-pharmaceutical`)

## Provenance

Content hash: b5f56592f7263a15cb8a82219725bfa14c5c8d952447f3c1610e454668c44f83
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
